EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Consun Pharmaceutical Group Limited (CPHGF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Consun Pharmaceutical Group Limited $4.13, price $1.78, upside +132.0%, quality 82 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Hong Kong

CP Consun Pharmaceutical Group Limited logo Some data Sep 24, 2026

Consun Pharmaceutical Group Limited

CPHGF · US

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value $4.13 · Strongly undervalued (+132.0%)
✓Quality 82/100
✓Healthy Growth (revenue 5y +14.3 %/yr)
✓Highly profitable · 31.6% net margin (TTM)
✓generates free cash flow
✓Ranks above peers (10/12)
✓Wide moat 81/100
!Insider activity 45/100
!Evidence only medium, so the estimate is less certain
Watch Consun Pharmaceutical Group Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.80 $0.9397 Fair Value $4.13 Dec 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

21‑month range $0.9397 – $1.80 · fair‑value band $2.56 – $6.89 · the $1.78 price screens below the $4.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Consun Pharmaceutical Group in your weekly email

Every Wednesday you see whether Consun Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical.

Show more

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Stock analysis

Consun Pharmaceutical Group Limited (CPHGF) currently trades at $1.78, while our model-based Fair Value estimate is $4.13, implying the stock looks roughly 56.9% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $4.13 per share, and 21 of the 24 models we run sit above the $1.78 price.

Bear case: the Asset-Based group reads lowest at $0.5400, and 3 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $2.56 (bear) to $6.89 (bull), the price of $1.78 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 82/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Consun Pharmaceutical Group Limited reported revenue of 3.4B CNY in FY2025 versus 2.0B CNY in FY2021, a compound +13.7%/yr. Reported net income was 1.1B CNY in FY2025, compounding +16.3%/yr from FY2021.

Key figures

Market cap $1.5B · P/E ratio 9.9 · P/S ratio 3.12 · EPS (TTM) $0.1800 · Net margin 31.5% · Return on equity 23.6% · Return on assets (EBIT) 15.8% · Operating margin 34.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).

What moves the price

The share trades about 1% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 132%, CPHGF screens cheaper than that median.

Fair Value models

Bear $2.56 Fair Value $4.13 Bull $6.89
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $2.50 $4.26 $7.13 76
Growth DCF $2.44 $3.93 $6.18 74
Owner Earnings $2.36 $4.03 $6.73 72
All 24 models by family
DCF Models
FCF DCF $2.50 $4.26 $7.13 76
Owner Earnings $2.36 $4.03 $6.73 72
5Y Revenue Exit $1.85 $2.95 $4.45 69
5Y EBITDA Exit $2.38 $4.11 $6.31 71
5Y P/E Exit $2.91 $5.24 $7.99 67
10Y Revenue Exit $2.02 $3.12 $4.82 63
10Y EBITDA Exit $2.39 $3.92 $6.31 64
10Y P/E Exit $2.72 $4.69 $7.64 60
Earnings-Based
Graham-Dodd $1.30 $6.93 $9.60 63
Lynch FV $1.91 $2.73 $3.55 61
PEG = 1.0 $1.91 $2.73 $3.55 57
EPV $1.51 $1.69 $1.84 68
Multiples
P/E Multiple $3.16 $4.21 $5.27 63
P/S Multiple $1.59 $2.13 $2.66 58
P/B Multiple $2.44 $3.26 $4.07 55
EV/EBIT $2.83 $3.70 $4.57 63
EV/EBITDA $2.49 $3.25 $4.01 64
EV/Revenue $1.49 $2.04 $2.59 51
Asset-Based
NCAV (Graham) $0.4000 $0.5400 $0.8100 51
Growth DCF
Growth DCF $2.44 $3.93 $6.18 74
Rev-Margin DCF $1.85 $2.93 $4.40 69
Economic Profit
Residual Income $1.04 $1.44 $2.58 72
ROIC Compounder $1.68 $2.10 $2.60 70
Growth Earnings
Growth-Adj P/E $2.89 $4.13 $5.37 67

Open the full fair value analysis →

Notify me when CPHGF reaches fair value

Put CPHGF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 82/100

Of which business quality 80 · Market factors (momentum, volatility) 79

Profitability 77
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 85
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 68
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 72
Price trend over the last 3–12 months (market factor)
52W Momentum 99
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 34%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −8.6% a year for the price and +9.0% for the forecasts.
Forecast 2026 (sales)+13.6%
Forecast 2027 (sales)+12.1%
Projected 2028 (sales)+10.8%
Projected 2029 (sales)+9.6%
Projected 2030 (sales)+8.3%

Watch CPHGF, get fair value alerts →

Compare Consun Pharmaceutical Group Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 569 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 82 · Top 25%
Fair Value upside +126.4% · Top 25%
Profitability
Return on equity (TTM) 23.6% · Top 25%
Return on assets 11.7% · Top 25%
Net margin (TTM) 31.6% · Top 25%
Operating margin (TTM) 34.5% · Top 25%
Growth and dividend
Revenue growth 8.8% · Above median
Dividend yield (TTM) 39.8% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 9.9× · Cheapest 25%
P/B 2.21× · Pricier than median
P/S (TTM) 2.93× · Pricier than median
P/FCF 8.8× · Cheapest 25%
EV/EBITDA 7.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 14
FUTURE (revenue growth)44 · sector 26
PAST (return on equity)94 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Consun Pharmaceutical Group Limited · Fair Value
$4.13 +57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Consun Pharmaceutical Group Limited Fair Value". https://www.fairvalue-calculator.com/stock/CPHGF

Frequently asked questions

Is Consun Pharmaceutical Group Limited (CPHGF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.13 versus the last price from Sep 25, 2026 of $1.78, about +132% upside (undervalued).
What is the fair value of CPHGF?
Our model-based fair value for Consun Pharmaceutical Group Limited is $4.13 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $1.78.
What is the quality score of CPHGF?
Consun Pharmaceutical Group Limited has a Quality Score of 82/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Consun Pharmaceutical Group Limited (CPHGF)?
Our model-based price target is the fair value of $4.13 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $2.56, optimistic scenario $6.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Consun Pharmaceutical Group Limited stock forecast for 2026?
Our models put fair value at $4.13, about +132% upside versus the last price from Sep 25, 2026 of $1.78 (undervalued). Cautious scenario $2.56, optimistic scenario $6.89. The calculation is refreshed regularly with new filings.
What is the revenue of Consun Pharmaceutical Group Limited (CPHGF)?
Consun Pharmaceutical Group Limited reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Consun Pharmaceutical Group Limited (CPHGF)?
For today's price to be fair in a discounted-cash-flow model, Consun Pharmaceutical Group Limited would have to grow free cash flow by -7.1 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CPHGF use?
Our models discount Consun Pharmaceutical Group Limited at 9.8 %: a base by market capitalisation (small), damped by beta 0.47, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Consun Pharmaceutical Group Limited that is -7.1 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Consun Pharmaceutical Group Limited (CPHGF) delivered so far?
Over the past 5 years revenue at Consun Pharmaceutical Group Limited grew +14.3 % a year. The price currently implies -7.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Consun Pharmaceutical Group Limited (CPHGF) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Consun Pharmaceutical Group Limited (-7.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Consun Pharmaceutical Group Limited (CPHGF)?
The free-cash-flow yield on the price is 11.40 %: that much free cash flow Consun Pharmaceutical Group Limited produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Consun Pharmaceutical Group Limited (CPHGF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Consun Pharmaceutical Group Limited it is $4.13 per share (as of Sep 24, 2026), against a price of $1.78. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Consun Pharmaceutical Group Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CPHGF trades below its calculated fair value: price $1.78, fair value $4.13, a gap of about +132% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CPHGF?
No. The price is what the market pays today ($1.78); the fair value is what the company's own numbers justify ($4.13). For Consun Pharmaceutical Group Limited the two are $2.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Consun Pharmaceutical Group Limited worth?
The market values Consun Pharmaceutical Group Limited at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $1.78; our models calculate a fair value of $4.13 per share.
What do the bullish and bearish scenarios say about CPHGF?
Our models span a range for Consun Pharmaceutical Group Limited: cautious scenario $2.56, base $4.13, optimistic $6.89 per share (as of Sep 24, 2026, price $1.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CPHGF?
Consun Pharmaceutical Group Limited trades at a price-to-earnings ratio of 9.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.13 is built from several models across several years. Other multiples: P/B 2.2, P/S 2.9, EV/EBITDA 7.3.
How solid is the balance sheet of Consun Pharmaceutical Group Limited (CPHGF)?
Balance-sheet figures for Consun Pharmaceutical Group Limited (as of Sep 24, 2026): return on equity 23.6%. They feed the Quality Score of 82/100, which measures business quality independently of the share price.
How far is CPHGF from its 52-week high?
Consun Pharmaceutical Group Limited trades at $1.78, about 1% below its 52-week high of $1.80 and 64% above the low of $1.09 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $4.13 is for.
Which stocks are comparable to Consun Pharmaceutical Group Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Consun Pharmaceutical Group Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $1.78, calculated fair value $4.13 (+132%), Quality Score 82/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CPHGF calculated?
We run Consun Pharmaceutical Group Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.13, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Consun Pharmaceutical Group Limited currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Consun Pharmaceutical Group Limited (CPHGF)?
The latest price we hold is from Sep 25, 2026 and stands at $1.78. Our model-based fair value is $4.13, about +132% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Consun Pharmaceutical Group Limited right now?
The rarer combination: high quality (82/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($2.56). The market is more pessimistic than our downside scenario. The model range is unusually wide ($2.56 to $6.89). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Consun Pharmaceutical Group Limited

How large is the market capitalisation of Consun Pharmaceutical Group Limited (CPHGF)?
The market capitalisation of Consun Pharmaceutical Group Limited is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Consun Pharmaceutical Group Limited (CPHGF)?
The price-to-sales ratio of Consun Pharmaceutical Group Limited is 3.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Consun Pharmaceutical Group Limited (CPHGF)?
Earnings per share at Consun Pharmaceutical Group Limited are $0.1800 (price ÷ EPS = P/E 9.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Consun Pharmaceutical Group Limited (CPHGF)?
The net margin of Consun Pharmaceutical Group Limited is 31.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Consun Pharmaceutical Group Limited (CPHGF)?
The return on equity (ROE) of Consun Pharmaceutical Group Limited is 23.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Consun Pharmaceutical Group Limited (CPHGF)?
On an EBIT basis the return on assets of Consun Pharmaceutical Group Limited is 15.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Consun Pharmaceutical Group Limited (CPHGF)?
The operating margin of Consun Pharmaceutical Group Limited is 34.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Consun Pharmaceutical Group Limited (CPHGF)?
Revenue at Consun Pharmaceutical Group Limited is growing +8.8% versus a year earlier (3y avg +13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Consun Pharmaceutical Group Limited (CPHGF)?
Earnings per share at Consun Pharmaceutical Group Limited are growing +13.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Consun Pharmaceutical Group Limited in the live analysis

One click puts Consun Pharmaceutical Group Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.